Key Insights - The report highlights a selection of stocks for August, including companies like SF Holding, Satellite Chemical, and Anji Technology, indicating potential investment opportunities in these firms [1] - The report emphasizes the steady growth of Tongcheng Travel, with Q2 2025 revenue reaching 4.669 billion yuan, a year-on-year increase of 10.0%, and an adjusted net profit of 775 million yuan, up 18.0% [3][8] - Nanya Technology's performance in Q2 2025 shows significant growth, with revenue of 2.305 billion yuan, a year-on-year increase of 43.06%, and a net profit of 87 million yuan, up 57.69% [13][14] - East China Pharmaceutical's revenue for the first half of 2025 was 21.675 billion yuan, a 3.39% increase year-on-year, with a net profit of 1.815 billion yuan, up 7.01% [18][19] Industry Performance - The report provides an overview of industry performance, with the telecommunications sector leading with a 4.85% increase, followed by non-ferrous metals at 4.63% and real estate at 3.32% [4] - The Shanghai Composite Index closed at 3883.56, reflecting a 1.51% increase, while the Shenzhen Component Index rose by 2.26% to 12441.07 [4] Company-Specific Highlights - Tongcheng Travel's core OTA business showed robust growth, with Q2 2025 OTA revenue reaching 4.01 billion yuan, a 13.7% increase year-on-year [9] - Nanya Technology's high-end product demand is driven by AI applications, with significant growth in high-end copper-clad laminate sales [15][16] - East China Pharmaceutical's innovative products are entering a harvest phase, with a notable increase in revenue from innovative products, reaching 1.084 billion yuan, a 59% year-on-year growth [20][21]

买入 原评级：买入 市场价格:人民币 45.71 板块评级:强于大市 股价表现 (%) 今年 至今 1 个月 3 个月 12 个月 绝对 37.7 2.9 8.6 51.5 相对深圳成指 19.6 (5.4) (7.2) 6.6 发行股数 (百万) 1,754.08 流通股 (百万) 1,751.94 总市值 (人民币 百万) 80,178.86 3 个月日均交易额 (人民币 百万) 636.19 主要股东持股比例 (8%) 5% 19% 32% 45% 59% Aug-24 Sep-24 Oct-24 Nov-24 Jan-25 Feb-25 Mar-25 Apr-25 May-25 Jun-25 Jul-25 Aug-25 华东医药 深圳成指 资料来源：公司公告， Wind ，中银证券 以 2025 年 8 月 21 日收市价为标准 医药生物 | 证券研究报告 — 业绩评论 2025 年 8 月 25 日 000963.SZ 相关研究报告 《华东医药》20250424 《华东医药》20241028 《华东医药》20240816 中银国际证券股份有限公司 具备证券投资咨询业务资格 医药生物：化学制药 证券分 ...

Core Viewpoint - Huadong Medicine reported a steady growth in its financial performance for the first half of 2025, with revenue reaching 21.675 billion yuan, a year-on-year increase of 3.39%, and a net profit of 1.815 billion yuan, up 7.01% [1] Financial Performance - The company achieved a total revenue of 21.675 billion yuan in the first half of 2025, reflecting a 3.39% increase year-on-year [1] - The net profit attributable to shareholders was 1.815 billion yuan, marking a 7.01% growth, while the net profit excluding non-recurring items was 1.762 billion yuan, up 8.40% [1] - A mid-year dividend of 614 million yuan is proposed, representing 33.83% of the net profit for the first half of 2025 [1] Business Growth and Product Commercialization - Huadong Medicine's core subsidiary, Zhongmei Huadong, reported a revenue of 7.317 billion yuan, a 9.24% increase, and a net profit of 1.580 billion yuan, up 14.09% [2] - The innovative product sales and agency service revenue reached 1.084 billion yuan, with a significant growth of 59% [2] - The CAR-T product, Zekai Ze, has expanded its market coverage, with over 20 provinces certified and more than 100 insurance projects included for reimbursement [2] R&D and Innovation - The company invested 1.484 billion yuan in R&D, a 33.75% increase, with direct R&D spending at 1.174 billion yuan, up 54.21% [6] - Huadong Medicine is advancing over 80 innovative drug pipelines, focusing on oncology, endocrinology, and autoimmune diseases [6][7] - The ADC product pipeline is progressing well, with several candidates in clinical trials and receiving orphan drug designation from the FDA [8] Industrial Microbiology and Aesthetic Medicine - The industrial microbiology segment achieved sales of 368 million yuan, a 29% increase, with significant growth in various sub-segments [10] - The aesthetic medicine division has launched multiple products, with strong market reception and ongoing registration efforts for new products [11][12] - The company aims to enhance its global presence and continue driving innovation in both pharmaceutical and aesthetic sectors [12]